HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Phthalates Safety Assessment Reopened By CIR

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Ingredient Review Expert Panel unanimously agreed to formally reopen its safety assessment of dibutyl, dimethyl and diethyl phthalates at a meeting in Washington, D.C. June 18-19

You may also be interested in...



Phthalates Group “Safe As Used” In Cosmetics, CIR Concludes

The Cosmetic Ingredient Review Expert Panel unanimously reaffirmed its original safety assessment that dibutyl, dimethyl and diethyl phthalates are "safe as used" in cosmetics at a meeting in Washington, D.C. Nov. 18-19

Phthalates Group “Safe As Used” In Cosmetics, CIR Concludes

The Cosmetic Ingredient Review Expert Panel unanimously reaffirmed its original safety assessment that dibutyl, dimethyl and diethyl phthalates are "safe as used" in cosmetics at a meeting in Washington, D.C. Nov. 18-19

Phthalates spotlight

Controversy over phthalates safety will return to the forefront Nov. 19, when health advocates stage a news conference in Washington, D.C. urging industry to stop use of the ingredient in cosmetics. Briefing will coincide with Cosmetic Ingredient Review Expert Panel meeting in which board plans to consider phthalate safety. CIR reopened its safety assessment of dibutyl, diethyl and dimethyl phthalates in June (1"The Rose Sheet" June 24, 2002, p. 7)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel